SPORE in Prostate Cancer

Publications

Found 90 results

Filters: First Letter Of Last Name is B [Clear All Filters]

2018

Sailer V, Schiffman MH, Kossai M, Cyrta J, Beg S, Sullivan B, Pua BB, Lee KSteve, Talenfeld AD, Nanus DM et al.. 2018. Bone biopsy protocol for advanced prostate cancer in the era of precision medicine.. Cancer. 124(5):1008-1015.

Conteduca V, Sigouros M, Sboner A, Pritchard CC, Beltran H. 2018. BRCA2-Associated Prostate Cancer in a Patient With Spinal and Bulbar Muscular Atrophy.. JCO Precis Oncol. 2

Liu D, Takhar M, Alshalalfa M, Erho N, Shoag J, Jenkins RB, R Karnes J, Ross AE, Schaeffer EM, Rubin MA et al.. 2018. Impact of the SPOP Mutant Subtype on the Interpretation of Clinical Parameters in Prostate Cancer.. JCO Precis Oncol. 2018

Liu D, Takhar M, Alshalalfa M, Erho N, Shoag J, Jenkins RB, Karnes J, Ross AE, Schaeffer EM, Rubin MA et al.. 2018. Impact of the SPOP Mutant Subtype on the Interpretation of Clinical Parameters in Prostate Cancer. JCO Precision Oncology.

Arora K, Barbieri CE. 2018. Molecular Subtypes of Prostate Cancer.. Curr Oncol Rep. 20(8):58.

Puca L, Bareja R, Prandi D, Shaw R, Benelli M, Karthaus WR, Hess J, Sigouros M, Donoghue A, Kossai M et al.. 2018. Patient derived organoids to model rare prostate cancer phenotypes.. Nat Commun. 9(1):2404.

Puca L, Bareja R, Prandi D, Shaw R, Benelli M, Karthaus WR, Hess J, Sigouros M, Donoghue A, Kossai M et al.. 2018. Patient derived organoids to model rare prostate cancer phenotypes.. Nat Commun. 9(1):2404.

Puca L, Bareja R, Prandi D, Shaw R, Benelli M, Karthaus WR, Hess J, Sigouros M, Donoghue A, Kossai M et al.. 2018. Patient derived organoids to model rare prostate cancer phenotypes.. Nat Commun. 9(1):2404.

Beltran H, Oromendia C, Danila DC, Montgomery B, Hoimes C, Szmulewitz RZ, Vaishampayan U, Armstrong AJ, Stein M, Pinski J et al.. 2018. A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers.. Clin Cancer Res.

Beltran H, Oromendia C, Danila DC, Montgomery B, Hoimes C, Szmulewitz RZ, Vaishampayan U, Armstrong AJ, Stein M, Pinski J et al.. 2018. A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers.. Clin Cancer Res.

Beltran H, Oromendia C, Danila DC, Montgomery B, Hoimes C, Szmulewitz RZ, Vaishampayan U, Armstrong AJ, Stein M, Pinski J et al.. 2018. A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers.. Clin Cancer Res.

Shoag J, Liu D, Blattner M, Sboner A, Park K, Deonarine L, Robinson BD, Mosquera JMiguel, Chen Y, Rubin MA et al.. 2018. SPOP mutation drives prostate neoplasia without stabilizing oncogenic transcription factor ERG.. J Clin Invest. 128(1):381-386.

Shoag J, Liu D, Blattner M, Sboner A, Park K, Deonarine L, Robinson BD, Mosquera JMiguel, Chen Y, Rubin MA et al.. 2018. SPOP mutation drives prostate neoplasia without stabilizing oncogenic transcription factor ERG.. J Clin Invest. 128(1):381-386.

2017

Pisapia DJ, Salvatore S, Pauli C, Hissong E, Eng K, Prandi D, Sailer V-W, Robinson BD, Park K, Cyrta J et al.. 2017. Next-Generation Rapid Autopsies Enable Tumor Evolution Tracking and Generation of Preclinical Models.. JCO Precis Oncol. 2017

Pisapia DJ, Salvatore S, Pauli C, Hissong E, Eng K, Prandi D, Sailer V-W, Robinson BD, Park K, Cyrta J et al.. 2017. Next-Generation Rapid Autopsies Enable Tumor Evolution Tracking and Generation of Preclinical Models.. JCO Precis Oncol. 2017